Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury.

Vanessa D'Antongiovanni,Luca Antonioli,Laura Benvenuti,Carolina Pellegrini,Clelia Di Salvo,Marco Calvigioni,Adelaide Panattoni,Larisa Ryskalin,Gianfranco Natale,Sebastiano Banni,Gianfranca Carta,Emilia Ghelardi,Matteo Fornai

British journal of pharmacology（2023）

引用 0|浏览24

暂无评分

摘要

Treatment with S. boulardii CNCM I-745 prevents diclofenac-induced enteropathy through anti-inflammatory and antioxidant activities. Such effects are likely to be related to increased tissue butyrate bioavailability, through an improvement of butyrate uptake by the enteric mucosa.

查看译文

关键词

enteropathy, intestinal damage, microbiota, nonsteroidal anti-inflammatory drugs, probiotics, Saccharomyces boulardii

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要